ProCE Banner Activity

SOLAR: Switch From BIC/TAF/FTC to LA CAB + RPV in Virologically Suppressed Persons With HIV

Capsule Summary
Conference Coverage
Slideset

At 12-month analysis, LA CAB + RPV administered IM every 2 months demonstrated noninferior efficacy by FDA snapshot analysis and improved patient satisfaction vs BIC/FTC/TAF.

Released: February 27, 2023

Expiration: February 26, 2024

No longer available for credit.
Begin Activity

Share

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

Merck & Co., Inc.

ViiV Healthcare